Evecxia

Evecxia Therapeutics is a biopharmaceutical company focused on serotonin synthesis amplification as a therapeutic approach in psychiatry. The company positions itself as the first dedicated to realizing the therapeutic potential of amplifying production of 5-hydroxytryptamine (5-HT, serotonin) for the treatment of mental illness, targeting patients with disabling conditions that are not adequately addressed by currently available therapies.

The scientific premise is that widely used antidepressants, including selective serotonin reuptake inhibitors (SSRIs such as Prozac) and serotonin-norepinephrine reuptake inhibitors (SNRIs such as Cymbalta), enhance serotonin neurotransmission only modestly and inconsistently across patients, which the company links to their modest and inconsistent efficacy. 5-HTP is the natural rate-limiting precursor of serotonin and has shown promise in experimental clinical settings across multiple brain disorders, most notably as an adjunctive (add-on augmentation) therapy in depression when an antidepressant alone provides inadequate relief. Native 5-HTP, however, is too short-acting and poorly absorbed to function as a practical drug therapy.

Evecxia is developing novel proprietary drug delivery technologies intended to overcome those pharmacokinetic limitations and enable the therapeutic properties of 5-HTP, describing its 5-HTP-based drugs as the first drug class designed to amplify production of natural brain serotonin to treat mental illnesses.